Opinion on Pharmaceuticals in South and Central America

Published within

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

FIGO 2009: expert backing for HRT for menopausal symptoms is welcome news

The debate regarding the use of HRT in postmenopausal women and its safety was very much a central topic throughout this year's International Federation of Gynecology and Obstetrics conference. Despite market-leader Wyeth's absence from the meeting, the core message that HRT should continue to be given to women in need will benefit players in this market.

Published By Datamonitor
13 Oct 2009
Expert View
Expert View

FIGO 2009: focus moves towards cervical cancer and overactive bladder

Among the key developments at this year's International Federation of Gynecology and Obstetrics meeting, pharmaceutical companies aimed to improve awareness of overactive bladder. Elsewhere, the reduction of mortality due to cervical cancer emerged as a key theme among delegates, with discussions of vaccine strategies not only in the developed world but also in developing countries.

Published By Datamonitor
13 Oct 2009
CommentWire
CommentWire

Forest/Gedeon Richter: cariprazine's anti-manic efficacy does not guarantee bipolar market success

Top-line results from a Phase III clinical trial show that cariprazine is effective in treating acute bipolar mania. While this is encouraging, cariprazine does not appear to address the principal unmet need in the management of bipolar disorders: relieving bipolar depression. This factor is vital, as Forest and Gedeon will be entering a fiercely competitive and saturated market.

Published By Datamonitor
06 Oct 2011
Expert View
Expert View

Four more years: solanezumab to remain in Phase III

Solanezumab, Eli Lilly's experimental Alzheimer's antibody, is to be tested in another Phase III trial, targeting mild patients only. Discussions with the FDA have dissuaded Lilly from seeking immediate approval, although the path to market for the much-maligned drug now appears relatively straightforward, albeit 4 years later than scheduled.

Published By Datamonitor
13 Dec 2012
CommentWire
CommentWire

Genentech/Biogen Idec: ocrelizumab encouraging in trials but lacks differentiation

Partners Genentech and Biogen Idec have announced positive results from the Phase III STAGE trial of ocrelizumab in rheumatoid arthritis. The positive data come as no real surprise and Datamonitor expects that ocrelizumab will launch for rheumatoid arthritis. However, the drug will suffer from a lack of differentiation from other B cell therapies.

Published By Datamonitor
11 Dec 2009
Expert View
Expert View

Genentech/Biogen Idec: Rituxan fails Phase II/III SLE trial

Rituxan, the blockbuster drug from Genentech and Biogen Idec, is the latest casualty in the systemic lupus erythematosus indication, reaffirming the complexity of this disease. In a Phase II/III trial, it was unable to demonstrate clinical efficacy in patients with SLE. Although Datamonitor believes that Rituxan will continue to be used off-label, these results make approval much more difficult.

Published By Datamonitor
01 May 2008
CommentWire
CommentWire

Genentech/Roche/Chugai: Herceptin shows activity in gastric cancer

Already a widely used therapy in HER-2-positive breast cancer patients, Herceptin now has the potential to establish itself in the equivalent gastric cancer subset following positive survival results in a pivotal trial. However, with other top-selling targeted therapy drugs also in late-stage development for the same indication, competition is on the horizon.

Published By Datamonitor
18 Mar 2009
CommentWire
CommentWire

Genentech/Roche: new trial failure marks setback for Avastin growth prospects

Multi-blockbuster Avastin has once again failed to show improved disease-free survival in a Phase III study for early-stage colon cancer. Although this will not impact Avastin's dominance in already approved indications, it is a major setback for development in the lucrative adjuvant therapy market and provides an opportunity for Erbitux.

Published By Datamonitor
22 Sep 2010
ResearchWire
ResearchWire

Generic competition: brand erosion across the major markets

Published By Datamonitor
09 May 2007
CommentWire
CommentWire

Generic penicillins: boosted by FDA's back-to-basics for S.pneumoniae

According to the Infectious Disease Society of North America, the FDA has changed the 'breakpoints' used to determine the susceptibility cut-off for penicillins in the treatment of Streptococcus pneumoniae pneumonia. This will reinvigorate this largely genericized antibiotic class, and is indicative of increasing pressure on antibiotics as efforts are made to restrict antibiotic resistance.

Published By Datamonitor
30 Apr 2008

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

No help is available.